• infiltrating angiolipoma
• interferon alpha
• Kasabach-Merritt syndrome

We read with interest the paper by Akyuz and colleagues,¹ which described a 2 year old patient with a Kasabach-Merritt syndrome (KMS) secondary to an infiltrating angiolipoma, who was successfully treated with interferon alpha 2a (IFN-alpha).

The authors did not emphasise the increasing body of concerns associated with the use of IFN-alpha in children affected by KMS. Indeed, several authors have recently warned about potential adverse effects related to the use of this drug, the most worrisome being spastic diplegia.^2–4

Although IFN-alpha has been shown to be an …